Aventis Pharmaceuticals Inc.

Paul Angell

Yulin Chiang

Kenneth J Bordeau

John G Jurcak

Matthias Urmann

Horst Hemmerle

David Fink

James Hendrix

George Lee

Gregory Shutske

Nicola Collar

Thaddeus Nieduzak

Sharon Anne Jackson

James P Carey

Joseph T Strupczewski

Jean-Francois Sabuco

Jospeh T Strupczewski

Jean-Fancois Sabuco

George E Lee

James A Hendrix

Jackson Sharon Anne Anne

Kenneth K Bordeau

Joseph T c/o Sanofi-Aventis US Inc Strupczewski

The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine Dreceptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine Dreceptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine Dreceptors.

[object Object]

Growing community of inventors

Middletown, OH, United States of America

Paul Angell